Age-standardized net survival (NS) analysed melanoma-specific mortality by NRAS and KIT genotype.<h4>Results</h4>Of new melanomas diagnosed, 6.6% (6045/91 415) and 3.0% (2705/91 415) had an NRAS and KIT test registered. The gene discussed is KIT; the disease is melanoma.